Speakers:
– Jennifer Schneider, Chief Executive Officer, Centauri Therapeutics (UK)
– Rida Mourtada, Chief Executive Officer, Lytic Therapeutics (USA)
– Gregorio Iraola, Chief Executive Officer, Kinzbio (Uruguay)
Moderator:
Peter Seiler, Member of the Management Team, INCATE (Switzerland)
This webinar will feature three presentations from those developing non-traditional antibacterials as potential solutions to combat infections.
Presentation 1: Immune therapy for infectious disease (Jennifer Schneider)
– Role of the host in the success of antimicrobial treatment
– Opportunities to address infections in vulnerable patients
Presentation 2: Development of stapled antimicrobial peptides to treat MDR Gram-negative pathogens (Rida Mourtada)
– Antimicrobial peptides: An untapped resource of non-traditional antimicrobials
– Peptide stapling to generate highly selective antimicrobial peptides that target Gram-negative bacteria
– Lytica’s success in generating StAMPs that can be administered systemically to treat pneumonia
Presentation 3: Preventing the spread of ESKAPE pathogens in the built-environment using jumbo bacteriophages (Gregorio Iraola)
– Jumbo bacteriophages, phages with expanded genomes allowing them interesting biological properties.
– Kinzbio’s use of a proprietary jumbo phage pipeline to create a preventive technology aiming to cut the spread of EKSAPE pathogens through the built-environment.
– Applying this approach in Intensive Care Units showing the decrease of circulating bacteria.
This live webinar includes an interactive Q&A session.
Date and time:
22 August 2024 at 17:00-18:30 CEST.
Dedicated registration link here
